Vepdegestrant became the first approved PROTAC, degrading ER in ESR1-mutated ER+/HER2− metastatic breast cancer, supported by VERITAC‑2 and enabled by Guardant360 CDx selection. Zenocutuzumab ...
New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational ...
International trial led in part by Roswell Park tests ziftomenib with venetoclax and azacitidine, showing high response rates ...
Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in ...
Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed revumenib post-transplant shows favorable ...
ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once ...
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a global leader ...
So now, you know, we have competing standards of care in the frontline for AML, which is either high intensity induction or ...
With the publication of the long-term data from the RELAZA2 study, a research program developed over many years by Dresden ...
Long-term RELAZA2 data showed MRD-guided therapy may improve outcomes for AML and MDS patients through earlier intervention.
As evidence continues to evolve, optimising sequencing, duration, MRD-guided use, and combination approaches will be important areas of focus to improve patient outcomes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results